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Regulation of cell survival by sphingosine-1-phosphate
receptor S1P1 via reciprocal ERK-dependent
suppression of Bim and PI-3-kinase/protein kinase
C-mediated upregulation of Mcl-1
C Rutherford1, S Childs1, J Ohotski2,3, L McGlynn3, M Riddick1, S MacFarlane1, D Tasker1, S Pyne2, NJ Pyne2, J Edwards3
and TM Palmer*,1
Although the ability of bioactive lipid sphingosine-1-phosphate (S1P) to positively regulate anti-apoptotic/pro-survival responses
by binding to S1P1 is well known, the molecular mechanisms remain unclear. Here we demonstrate that expression of S1P1
renders CCL39 lung fibroblasts resistant to apoptosis following growth factor withdrawal. Resistance to apoptosis was
associated with attenuated accumulation of pro-apoptotic BH3-only protein Bim. However, although blockade of extracellular
signal-regulated kinase (ERK) activation could reverse S1P1-mediated suppression of Bim accumulation, inhibition of caspase-3
cleavage was unaffected. Instead S1P1-mediated inhibition of caspase-3 cleavage was reversed by inhibition of
phosphatidylinositol-3-kinase (PI3K) and protein kinase C (PKC), which had no effect on S1P1 regulation of Bim. However,
S1P1 suppression of caspase-3 was associated with increased expression of anti-apoptotic protein Mcl-1, the expression of
which was also reduced by inhibition of PI3K and PKC. A role for the induction of Mcl-1 in regulating endogenous S1P receptor-
dependent pro-survival responses in human umbilical vein endothelial cells was confirmed using S1P receptor agonist FTY720-
phosphate (FTY720P). FTY720P induced a transient accumulation of Mcl-1 that was associated with a delayed onset of caspase-3
cleavage following growth factor withdrawal, whereas Mcl-1 knockdown was sufficient to enhance caspase-3 cleavage even in
the presence of FTY720P. Consistent with a pro-survival role of S1P1 in disease, analysis of tissue microarrays from ER
þ breast
cancer patients revealed a significant correlation between S1P1 expression and tumour cell survival. In these tumours,
S1P1 expression and cancer cell survival were correlated with increased activation of ERK, but not the PI3K/PKB pathway.
In summary, pro-survival/anti-apoptotic signalling from S1P1 is intimately linked to its ability to promote the accumulation of
pro-survival protein Mcl-1 and downregulation of pro-apoptotic BH3-only protein Bim via distinct signalling pathways. However, the
functional importance of each pathway is dependent on the specific cellular context.
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D-erythro-sphingosine-1-phosphate (S1P) is a bioactive lipid
produced in large quantities by several cell types, including
erythrocytes and activated platelets.1 It has also been found to
be an active constituent of high- and low-density lipoproteins
and may be responsible for their cytoprotective effects on
vascular endothelial cells (ECs).2 S1P is generated mainly by
hydrolysis of sphingomyelin and the sequential action of
ceramidase and sphingosine kinases 1 and 2 (SK1 and 2) on
ceramide and sphingosine.3 The effects of extracellular S1P
are mediated by a family of five G-protein-coupled receptors
termed S1P1–S1P5.
4,5
The clinical use of FTY720 (fingolimod), which is phos-
phorylated by SK2 to form the S1P receptor agonist FTY720-
phosphate (FTY720P) for management of relapsing-remitting
multiple sclerosis (MS), has demonstrated the utility of
targeting the S1P receptor family.5,6 However, maximising
the wider utility of S1P1-targeted drugs will require a greater
understanding of the key processes activated upon receptor
modulation.
S1P1 couples with the Gi family of guanine nucleotide-
binding regulatory proteins (G-proteins) to activate multiple
intracellular signalling pathways, including the extracellular
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signal-regulated kinases 1,2 (ERK1,2) and the phosphatidy-
linositol-3-kinase (PI3K) pathways.5,7 It has also been shown
that S1P1 in ECs stabilises adherens junctions and inhibits
sprouting angiogenesis to maintain nascent blood vessel
stability8,9 while S1P1 antagonism inhibits tumour vasculari-
sation.10 The importance of S1P1 in solid tumour progression
has also been demonstrated in recent studies that have
identified a feed-forward mechanism in which S1P1-mediated
induction of signal transducer and activator of transcription
3-activating genes, such as pleiotropic cytokine IL-6 and S1P1
itself, can drive tumour growth and ultimately metastasis.11–13
However, despite the importance of pro-survival signalling
downstream of S1P1, the mechanisms responsible remain
unclear.
The intrinsic apoptotic pathway is controlled by regulated
interactions between three classes of ‘B-cell lymphoma 2’
(Bcl-2) proteins: multi-domain pro-apoptotic proteins
(e.g., Bcl-2-associated X Protein (Bax), Bcl-2 homologous
antagonist/killer (Bak)), pro-survival proteins (e.g., Bcl-2,
Bcl-2-like protein 1 (Bcl-XL), myeloid cell leukaemia sequence 1
(Mcl-1)) and pro-apoptotic Bcl-2 homology domain 3 (BH3)-
only proteins (e.g., Noxa, p53-upregulated modulator of
apoptosis (PUMA), Bcl-2-modifying factor (Bmf), Bcl-XL/
Bcl-2-associated death promoter (Bad) and Bcl-2-interacting
mediator of cell death (Bim); reviewed in Chipuk et al.14 and
Giam et al.15). Although Bax and Bak are restrained by
interaction with pro-survival proteins, BH3-only proteins
function as sensors of cell stress via their activation in
response to pro-apoptotic stimuli.14,15 For example, the ‘extra
long’ Bim splice variant BimEL is induced following the
inhibition of protein kinase B (PKB)-mediated phosphorylation
of transcription factor FOXO3A that occurs following growth
factor withdrawal, leading to a reduced binding of 14-3-3
proteins, which triggers FOXO3A translocation to the nucleus
to initiate Bim transcription.16 In addition, ERK1,2-mediated
phosphorylation of BimEL promotes its dissociation from pro-
survival proteins, such as Mcl-1 and Bcl-XL, to enhance cell
survival17 and also primes BimEL for further phosphorylation
by ribosomal S6 kinase, which ultimately promotes BimEL
polyubiquitylation and proteasomal degradation.18
Despite the well-documented ability of S1P1 receptor
activation to increase survival in a variety of cell types, the
molecular mechanisms responsible have not been fully
characterised. In this study, we demonstrate that endogenous
and recombinant S1P1 is able to suppress levels of pro-
apoptotic BH3-only protein Bim via a mitogen-activated
protein/ERK kinase (MEK)/ERK1,2 pathway, and enhance
the accumulation of anti-apoptotic protein Mcl-1 via a PI3K-
mediated and protein kinase C (PKC)-mediated pathway.
These findings have clinical relevance, as S1P1 expression is
associated with enhanced ERK pathway activation and
reduced apoptosis in ERþ breast cancer tissue. Thus,
multiple pathways appear to be critical in determining the
ability of S1P1 to enhance cell survival.
Results and Discussion
S1P1 expression enhances survival of CCL39 cells
following growth factor withdrawal. As enhanced
survival, or a resistance to apoptosis, is a key aspect of
many pathologies, a greater understanding of the
mechanisms responsible for S1P1-mediated cell survival
responses at the molecular level is required to fully exploit
the possibility of therapeutically targeting this receptor in
disease. To examine S1P1 function, we initially utilised
CCL39 hamster lung fibroblasts stably expressing a myc
epitope-tagged human S1P1 receptor (Figure 1a). Receptors
were localised to the cell surface (Figure 1a) and no staining
was detectable in control CCL39 cells, thus confirming the
specificity of the immunostaining for S1P1 (data not shown).
Treatment of these cells with FTY720P was able to sustain a
concentration-dependent activation of the ERK1,2 pathway
(Figure 1b) with a pEC50¼ 10.52±0.32 (n¼ 3). This is
consistent with the sub nM affinity of ligand binding to
human S1P1
19 and the nM potency reported for activation of
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Figure 1 Functional expression of human S1P1 in CCL39 cells. (a) Left:
detergent-soluble cell extracts from control and S1P1-expressing CCL39 cells were
equalised for protein content before immunoblotting with anti-myc antibody 9E10 (to
detect myc epitope-tagged receptor) and GAPDH. Right: S1P1-expressing CCL39
cells were fixed and permeabilised for staining with 9E10 antibody and Alexa 488-
conjugated goat anti-mouse IgG before visualisation by confocal microscopy. Scale
bar¼ 20 microns. (b) Upper: control and S1P1-expressing CCL39 cells were
treated for 5 min with the indicated concentrations of S1P receptor agonist FTY720P
or vehicle (V) before the preparation of detergent-soluble cell extracts. Samples
were equalised for protein content before fractionation via SDS-PAGE and
subsequent immunoblotting with anti-Thr202/Tyr204 phospho-specific ERK1,2
antibodies as a surrogate marker of intracellular signalling. Equal protein loading
was assessed by determining total ERK1,2 levels. Lower: data are presented as
mean values±S.E. for n¼ 3 separate experiments. *Po0.05 versus identically
treated CCL39 controls
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downstream signalling at recombinant and endogenous
S1P1 receptors.
19,20 No ERK1,2 activation was detectable
in CCL39 neomycin-resistant clones (hereafter referred to as
‘controls’) indicating that the response to FTY720P was
mediated entirely by S1P1.
The intrinsic apoptotic responses of CCL39 cells upon serum
withdrawal have already been well characterised17,21,22
and therefore provides a useful system for examining the
effect of agents on S1P1 expression and activation. It was
noted that S1P1-expressing cells were viable after serum
withdrawal for up to 24 h, whereas control CCL39 cells were
apoptotic (Figure 2a). FACS analysis of cell cycle distributions
following propidium iodide (PI) staining confirmed that while
growth factor withdrawal produced a time-dependent increase
in the number of control cells with sub-G1 DNA, this response
was significantly inhibited in the CCL39/mycS1P1 cell line we
have used for most of our study (cell line 5A) and an additional
line (5B) (Figures 2b and c). This suggested that S1P1
expression conferred a resistance to serum withdrawal-
induced apoptosis in multiple CCL39 cell lines. Cell line 5A
was used for the remainder of the experiments presented in
this study.
As many features of apoptotic cell death are triggered
by caspases, we compared the effects of growth factor
withdrawal on DEVDase activity in lysates from control and
S1P1-expressing CCL39 cells. Growth factor removal pro-
duced an increase in DEVDase activity in cell lysates that was
attenuated by co-incubation with the caspase-3/7 inhibitor
Ac.DEVD-CHO (Figure 2d). However, the growth factor
withdrawal-induced increase in DEVDase activity in lysates
from S1P1-expressing cells was significantly reduced com-
pared with control CCL39 cells (Figure 2d). Consistent with
these observations, immunoblotting of detergent-soluble cell
lysates revealed that serum deprivation of control CCL39 cells
resulted in the time-dependent formation of cleaved activated
caspase-3, which was detectable at 6 h, maximal at 12 h and
sustained for at least 24 h (Figure 3a). However, serum
deprivation of S1P1-expressing cells had little effect on levels
of cleaved caspase-3 (Figure 3a). Consistent with previous
studies,21 the appearance of cleaved caspase-3 in growth
factor-deprived control CCL39 cells was preceded by the
accumulation of pro-apoptotic protein Bim. In parallel with the
effect on caspase-3 activation, Bim expression following
serum withdrawal was reduced in S1P1-expressing cells.
Interestingly, although expression levels of BH3-only protein
Noxa were initially low in control cells, serum deprivation
resulted a rapid accumulation of Noxa that was sustained up
to the last time point examined (24 h). Moreover, levels of
Noxa were high in S1P1-expressing cells and only decreased
significantly after serum deprivation for 12 h before returning
to the levels observed in cells maintained in normal growth
medium (Figure 3b). In contrast, levels of Bax were not altered
by either S1P1 expression or serum withdrawal (Figure 3a).
Levels of related BH3-only proteins Bmf and PUMA were
undetectable in either control or S1P1-expressing cells in the
presence or absence of serum (data not shown).
Pharmacology of S1P1 pro-survival response. First, we
determined whether the pro-survival effect of S1P1 expres-
sion was due to formation of endogenous S1P.23 However,
incubation with pan-SK inhibitor D,L-threo-dihydrosphingosine
(DHS)24 (10 mM) failed to reduce the ability of S1P1 to
suppress cleaved caspase-3 formation (Figure 4a). Thus,
resistance to apoptosis appears to be due to the action of
constitutively activated S1P1 rather than autocrine production
of S1P. To further examine the pharmacology of the
response, we utilised FTY720P and S1P1-modifying agent
SB649146, which has inverse agonist activity against
constitutive S1P1 receptor-dependent activation of Gi and
also blocks S1P-dependent activation of ERK1,2.25–27
Treatment of cells with SB649146 (5 mM) reduced
FTY720P-stimulated ERK1,2 phosphorylation in S1P1-
expressing CCL39 cells (Figure 4b: SB649146 reduced
1 nM FTY720P-stimulated ERK1,2 phosphorylation by
75±11%, n¼ 4 experiments, Po0.05). Treatment of S1P1-
expressing cells with FTY720P (0.1 mM) during growth factor
withdrawal did not further suppress caspase-3 cleavage over
that observed in serum-starved cells (Figure 4c) as this
response is maximal with growth factor withdrawal. However,
treatment of S1P1-expressing cells with SB649146 alone
significantly increased caspase-3 cleavage following serum
withdrawal compared with vehicle-treated cells (Figure 4c),
suggesting that SB649146 inhibits the ability of S1P1 to
constitutively limit apoptosis. The suppression of caspase-3
cleavage achieved by a combination of serum withdrawal
and FTY720P was only partially reversed by SB649146 and
this response was not consistently observed. Indeed,
FTY720P should compete and diminish the effect of
SB649146 and this was observed, thereby confirming that
both compounds are acting on S1P1.
S1P1 regulation of pro-apoptotic protein expression.
Caspase-3 cleavage is the final step in the intrinsic apoptotic
pathway typically triggered upon accumulation and/or activa-
tion of pro-apoptotic BH3-only proteins.14,15 As Bim accu-
mulation most closely paralleled the accumulation of cleaved
caspase-3 in control and S1P1-expressing CCL39 cells
following serum withdrawal (Figure 3a), we examined any
potential relationship between the two phenomena. Initially,
we compared the ability of a panel of signalling pathway
inhibitors to block the suppressive effects of S1P1 expression
on cleaved caspase-3 and Bim accumulation following
growth factor withdrawal.
S1P1 couples with multiple signalling pathways predomi-
nantly via activation of Gi proteins.
5,7 However, despite almost
abolishing ERK1,2 phosphorylation, inactivation of Gi proteins
with pertussis toxin did not completely reverse S1P1-mediated
suppression of caspase-3 cleavage, suggesting that S1P1-
mediated protection against caspase-3 activation is only
partially Gi dependent (Figure 5a).
Consistent with previous work in CCL39 cells,17,21 treat-
ment of S1P1-expressing cells with MAP/ERK kinase (MEK)
inhibitor U0126 during serum starvation abolished ERK1,2
phosphorylation and restored Bim expression to levels
comparable with those in serum-starved control cells
(Figure 5a). This would be consistent with the reported ability
of Bim to serve as a substrate for activated ERK1,2, an event
that precedes its dissociation from pro-survival proteins
and proteasomal degradation.17,18,28 However, the ability
of S1P1-expressing cells to limit the generation of cleaved
S1P1-mediated cell survival mechanisms
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caspase-3 was not altered by U0126 under conditions in
which it abolished ERK1,2 phosphorylation (Figure 5a).
Interestingly, despite significant suppression of Bim expres-
sion in S1P1-expressing cells, levels of phosphorylated
ERK1,2 in serum-starved S1P1-expressing cells versus
controls were comparable. Detailed analysis of changes in
phospho-ERK1,2 levels following serum withdrawal in control
and S1P1-expressing cells revealed that the decline in
phospho-ERK1,2 levels observed was marginally greater in
S1P1-expressing cells, with the difference reaching statistical
GAPDH
CC
L3
9
5A 5B
CCL39/mycS1P1
mycS1P1
CCL39
C
SF
CCL39/mycS1P1
Control SF 6 hr SF 24 hr
0
10
20
30
40
50
*
C SF 24 hrs
*
CE
LL
S 
W
IT
H 
SU
B-
G
1 
D
N
A
 (%
) CCL39
CCL39/mycS1P1 clone 5B
CCL39/mycS1P1 clone 5A
200
1000800600400
FL2-H
2000 1000800600400
FL2-H
200 2000 1000800600400
FL2-H
0
160
120
Co
un
ts
Co
un
ts
80
40
0
200
160
120
80
40
0
Co
un
ts
200
160
120
80
40
0
0
1
2
3
4
5
6
7
8
C      SF     SF      C      SF     SF
*
**
Ψ
**
CCL39 CCL39/mycS1P1
-        -       +         -        -        +
DEVDase Activity
D
EV
D
as
e 
A
CT
IV
IT
Y
(F
old
 in
cr
ea
se
 ov
er
 C
CL
39
 co
nt
ro
ls)
: 0.1μM AcDEVD-CHO
*
S1P1-mediated cell survival mechanisms
C Rutherford et al
4
Cell Death and Disease
significance at the 12-h time point (Figure 5b). As the
S1P1-mediated suppression of Bim is clearly MEK/ERK
dependent (Figure 5a) and thus consistent with previous
observations,17,18,21,28 our data would argue that S1P1
expression must trigger constitutive activation of a localised
pool of ERK in CCL39 cells that, although it comprises a small
proportion of the total ERK content, is essential for suppres-
sion of Bim. The existence of functionally discrete pools of
S1P1 receptors has been shown in murine embryonic
fibroblasts, airway smooth muscle cells and transfected
HEK293 cells.26,29 It is also consistent with observations of
activation of distinct subcellular pools of ERK1,2 by G-protein-
coupled receptors via both G-protein- and b-arrestin-
mediated processes.30,31
S1P1 is also known to activate PKB and conventional and
novel PKC isoforms32,33 and we found that levels of active Ser
473-phosphorylated PKB were elevated in S1P1-expressing
cells either in the presence or absence of serum (Figure 5c).
As these are involved in pro-survival responses (reviewed
in refs Zhang et al.34 and Griner and Kazanietz35), we
examined the effects of inhibiting these pathways individually
and in combination. Treatment of cells with conventional and
novel PKC inhibitor GF109203X produced a small but
significant reversal in the ability of S1P1 to limit caspase-3
cleavage. The effect of PI3K inhibitor LY294002 was greater
than that of GF109203X. However, in combination both
compounds completely reversed the effect of S1P1 expres-
sion and resulted in cleavage of caspase-3 to a level
comparable with that observed in serum-deprived control
CCL39 cells (Figure 5c). Importantly, treatment with
GF109203X and LY294002 alone did not change the effect
of serum withdrawal on Bim accumulation, whereas the
presence of both compounds produced only a small increase
in Bim, which did not reach the levels observed in control cells
(Figure 5c).
S1P1 specifically regulates levels of anti-apoptotic
protein Mcl-1. Previous studies have demonstrated a role
for Bim in triggering apoptosis in CCL39 cells following serum
deprivation.17,21 However, although S1P1 could suppress
Bim accumulation, restoration of Bim expression by treat-
ment with MEK inhibitor U0126 was not sufficient to increase
caspase-3 cleavage. Thus, the pro-survival effect of S1P1
was independent of its ability to suppress Bim, which
suggested that S1P1 must utilise additional mechanisms to
maintain cellular resistance to apoptosis even when Bim
levels are elevated. One possibility was that S1P1 could
induce the expression of anti-apoptotic/pro-survival proteins
capable of inhibiting Bim. Candidates included Mcl-1, Bcl-XL
and Bcl-2, which can sequester BH3-only proteins as well as
pro-apoptotic mediators such as Bax and Bak.14,15
Moreover, forced expression of either Mcl-1 or Bcl-2 has
been shown to reduce levels of sub-G1/apoptotic CCL39
cells following growth factor withdrawal.17 Indeed, the loss of
‘phosphatase and tensin homologue on chromosome 10’
expression in murine embryonic fibroblasts can protect
against serum withdrawal-induced apoptosis via upregulation
of Mcl-1.36
Therefore, we examined Mcl-1, Bcl-XL and Bcl-2 expres-
sion over the same time frame in which differences in cleaved
caspase-3 accumulation were apparent. In control CCL39
cells, serumwithdrawal produced a time-dependent decrease
in Mcl-1; levels were approximately 50% of those for cells
grown in serum at 24 h (Figure 6a). Interestingly, Mcl-1 levels
were elevated by approximately twofold in S1P1-expressing
cells in normal growthmedium versus control CCL39 cells and
remained so during growth factor withdrawal up to 24 h
(Figure 6a). In contrast, Bcl-2 and Bcl-XL expression levels
were comparable at all times after serum withdrawal
(Figure 6a).
Several aspects of Mcl-1 regulation also suggested its
possible involvement as a mediator of cell survival down-
stream of S1P1. First, Mcl-1 can be degraded by the
proteasome after polyubiquitylation by the SCFFBW7 E3
ubiquitin ligase complex following phosphorylation by glyco-
gen synthase kinase 3 (GSK3).37,38 Consequently, Mcl-1
accumulation following PKB-mediated phosphorylation and
inhibition of GSK3 is an important pro-survival signal.38 PKC
isoforms have also been shown to regulate Mcl-1 expres-
sion.39 Given that suppression of caspase-3 activation by
S1P1 was blocked by PI3K and PKC inhibitors (Figure 5c), we
examined their effects on Mcl-1 expression in S1P1-expres-
sing cells in the presence and absence of serum. Although
Mcl-1 levels were elevated in S1P1-expressing cells, treat-
ment with each inhibitor either alone or in combination elicited
significant decreases in Mcl-1 expression (Figure 6b) that
paralleled the observed changes in caspase-3 activation
(Figure 5c). Therefore, S1P1 induces Mcl-1 expression via
PI3K- and PKC-dependent pathways and this contributes to
the enhanced survival of S1P1-expressing cells upon serum
withdrawal.
To further examine a link between elevated Mcl-1 expres-
sion and resistance to apoptosis in S1P1-expressing cells,
we tested the effects of inhibiting new protein synthesis
on caspase-3 activation in control and S1P1-expressing
CCL39 cells. When serum-starved cells were switched to
Figure 2 S1P1-expressing CCL39 cells are resistant to growth factor withdrawal-induced apoptosis. (a) Phase contrast images of control and S1P1-expressing CCL39
cells maintained in normal growth medium after switching to either fresh growth medium (C) or serum-free medium (SF) for 24 h. Scale bar¼ 100 microns. (b) Detergent-
soluble cell extracts from control and S1P1-expressing CCL39 cell lines 5A and 5B were equalised for protein content before immunoblotting with anti-myc antibody 9E10 and
GAPDH. (c) Control and S1P1-expressing CCL39 cell lines 5A and 5B maintained in normal growth medium were switched to either serum-free medium or fresh growth
medium before fixation and staining with PI and FACS analysis of cell cycle status. Representative traces from control (purple) and clone 5A S1P1-expressing (green) CCL39
cells in either control growth medium or serum-free (SF) medium for the indicated times are shown along with the sub-G1 gates. Lower panel: data taken from n¼ 3
experiments showing the accumulation of sub-G1 cells. *Po0.05 versus cells grown in control medium, CPo0.05 versus CCL39 control cells at the indicated time point.
(d) Control and S1P1-expressing CCL39 cell line 5A were switched to either SF medium or fresh growth medium (C) for 16 h before preparation of protein-equalised cell
extracts for assay of DEVDase activity using DEVD-pNA as substrate in the presence or absence of caspase-3/7 inhibitor AcDEVD-CHO (0.1mM). Data are presented as
mean values±S.E. for n¼ 3 separate experiments. *Po0.05 versus CCL39 controls in normal growth medium, **Po0.05 versus cell extracts in the absence of
AcDEVD-CHO, CPo0.05 versus serum-starved CCL39 controls
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serum-free medium containing protein synthesis inhibitor
emetine, cleaved caspase-3 levels in control CCL39 cells
remained consistently elevated for up to 8 h (Figure 7a). In
contrast, the initially low levels of cleaved caspase-3 found in
S1P1-expressing cells increased until, by 4 h, they were
similar to those observed in control cells.Moreover, this occurred
despite parallel decreases in pro-apoptotic Bim expression in
both cell lines (Figure 7a). To determine whether changes in
Mcl-1 expression could explain increased caspase-3 activa-
tion in S1P1-expressing cells following emetine treatment, we
compared Mcl-1 levels in control and S1P1-expressing cells.
Interestingly, althoughMcl-1 protein levels remained relatively
stable in serum-starved control CCL39 cells following emetine
treatment, levels in S1P1-expressing cells were dramatically
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Figure 3 Regulation of pro-apoptotic protein expression in S1P1-expressing CCL39 cells. (a) Control and S1P1-expressing CCL39 cells were switched to serum-free
medium (SF) for the indicated times before preparation of detergent-soluble cell extracts. Samples were equalised for protein content before fractionation via SDS-PAGE and
subsequent immunoblotting with the indicated antibodies. Quantitation of cleaved caspase-3 and Bim expression normalised to GAPDH is presented as mean values±S.E.
for n¼ 3 separate experiments. *Po0.05 versus CCL39 control cells at the indicated time point. (b) Control and S1P1-expressing CCL39 cells were switched to SF medium
for the indicated times before preparation of detergent-soluble cell extracts. Samples were equalised for protein content before fractionation via SDS-PAGE and subsequent
immunoblotting with the indicated antibodies. Quantitation of Noxa expression normalised to GAPDH is presented as mean values±S.E. for n¼ 3 separate experiments.
*Po0.05 versus CCL39 control cells at the indicated time point
S1P1-mediated cell survival mechanisms
C Rutherford et al
6
Cell Death and Disease
reduced within 2 h despite being expressed at higher levels
initially than control cells. In contrast, levels of related anti-
apoptotic protein Bcl-XL remained constant (Figure 7b).
Importantly, the rapid downregulation of Mcl-1 preceded the
increase in cleaved caspase-3 observed in S1P1-expressing
cells (Figures 7a and b), suggesting that maintenance ofMcl-1
expression prevents caspase-3 activation thereby conferring
resistance to apoptosis.
Mcl-1 and endogenous S1P receptor regulation of
apoptosis in vascular ECs. To examine the potential
significance of Mcl-1 regulation in cells expressing endoge-
nous S1P1, we utilised human umbilical vein ECs (HUVECs)
as several studies have demonstrated S1P1 activation of
PKC and PI3K pathways in these cells.32,33,40 Growth factor
removal resulted in a time-dependent increase in levels of
cleaved caspase-3 that peaked at 3 h and was sustained for
up to 6 h (Figure 8a). Inclusion of S1P receptor agonist
FTY720P triggered a rapid yet transient accumulation of
Mcl-1, which accompanied a delayed accumulation of Bim
and cleaved caspase-3 versus vehicle-treated controls
(Figure 8a). To examine the role of Mcl-1 accumulation in
repressing caspase-3 cleavage, we tested the effects of
siRNA-mediated Mcl-1 knockdown. Importantly, the ability of
FTY720P to increase Mcl-1 expression was significantly
attenuated in Mcl-1 siRNA- versus non-targeting control
siRNA-transfected HUVECs. This resulted in a significant
increase in cleaved caspase-3 levels and blocked the ability
of FTY720P to inhibit caspase-3 activation (Figure 8b).
S1P1 expression and resistance to apoptosis in oestrogen
receptor-positive (ERþ ) breast cancer. The ability to
evade apoptosis is one of the hallmarks of cancer41 and
increased expression of pro-survival proteins can promote
resistance of mammary tumours to chemo- and radio-
therapies.42,43 As enhanced plasma membrane expression
of S1P1 in ER
þ breast cancer is associated with poor
prognosis in patients treated with tamoxifen,44 we examined
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the relationship between S1P1 expression and apoptotic
status in tissue microarrays (TMAs) from a previously
described cohort of ERþ breast cancer patients.45
Our experiments in CCL39 cells and HUVECs suggested
that S1P1 could potentially enhance cell survival via either a
MEK/ERK1,2-dependent suppression of BH3-only protein
Bim expression or a PI3K- and PKC-mediated accumulation
of pro-survival protein Mcl-1. Consistent with a pro-survival
role of S1P1 in ER
þ breast cancer, tumours with high levels of
S1P1 expression in the plasma membrane were correlated
with significantly lower levels of apoptosis-derived DNA
fragments in TMAs (Figure 9a). Analysis of candidate S1P1-
activated signalling pathways revealed a significant associa-
tion between high levels of S1P1 expression in the plasma
membrane and elevated levels of Ser338-phosphorylated
active Raf-1 in cytoplasmic and nuclear compartments
(Figure 9b). As might be expected, high levels of Ser338-
phosphorylated active Raf-1 in the cytoplasm and nucleus
were associated with elevated levels of Thr202/Tyr204
phosphorylated active ERK1,2 in both compartments
(Figure 9c). Importantly, high levels of phosphorylated active
ERK1,2 were also associated with a significantly lower
apoptosis-derived DNA fragments in tumour samples
(Figure 9d), whereas no significant association between low
apoptosis scores and enhanced phosphorylation of PKB was
observed in this cohort of patients (data not shown). Although
these data are essentially correlative and not necessarily
indicative of a causal relationship, taken together they would
argue that while S1P1 can initiate multiple intracellular pro-
survival signals, elevated levels of S1P1 in ER
þ breast
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tumours might suppress apoptotic cell death predominantly
via a Raf-1/MEK/ERK1,2 pathway.
In summary, we have identified multiple mechanisms by
which S1P1 expression and activation can enhance cell
survival. First, we have demonstrated a critical role for Mcl-1 in
enhancing cell survival following growth factor withdrawal in
two cell models. Several studies have demonstrated elevated
Mcl-1 in different cancer settings, including multiple
myeloma46 and hepatocellular carcinoma,47 and its increased
expression may underlie the resistance of some tumours to
BH3 mimetic drug ABT-737, which binds Mcl-1 relatively
poorly compared with other anti-apoptotic Bcl-2 family
members.48,49 In addition, the importance of Mcl-1 in
promoting the EC survival necessary for angiogenesis
has been demonstrated by studies showing that its
downregulation in ECs contributes to the pro-apoptotic and
anti-angiogenic effects of 3,6-di(2,3-epoxypropoxy)xanthone
and sorafenib.50,51 Therefore, the ability of S1P1 to enhance
Mcl-1 expression may have an important role in the control of
EC viability and stabilisation of mature vasculature by this
receptor.8,9
Second, we have shown that in ERþ breast cancers, high
S1P1 expression and resistance to apoptosis is linked to
hyperactivation of the ERK1,2 pathway, which is a key
suppressor of pro-apoptotic BH3-only protein Bim. Therefore,
it might be beneficial to target these pathways to treat ERþ
breast cancers for which significant correlations between poor
prognosis and high expression levels of SK1, which catalyses
formation of S1P, and the S1P receptors S1P1 and S1P3 have
been reported for specific patient cohorts.45 Our delineation of
distinct ERK1,2- and PI3K/PKC-dependent processes down-
stream of S1P1 also suggest that S1P1-selective antagonists
may be useful in attenuating multiple pro-survival pathways
not only in tumour cells but also in ECs within the tumour
vasculature. Indeed, it has recently been demonstrated that
the SK-phosphorylated product of S1PR antagonist pro-drug
VPC03090 inhibits mammary tumour growth in mice,52 further
supporting the hypothesis that S1PRs are potentially
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efficacious therapeutic targets for developing new breast
cancer treatments.
Materials and methods
Materials. FTY720P was obtained from Caymen Chemical (Ann Arbor, MI,
USA). Antibodies were from the following sources: Bim (Chemicon, Temecula, CA,
USA; cat. no. AB17003), Mcl-1 (Rockland, Gilbertsville, PA, USA; cat. no.
600-401-394), cleaved caspase-3 (Asp175; Cell Signaling Technology, Danvers,
MA, USA; cat. no. 9661), Ser473 phospho-specific PKB (Cell Signaling
Technology, cat. no. 9271), total ERK1,2 (Cell Signaling Technology, cat. no.
9102), Thr202/Tyr204 phospho-specific ERK1,2 (Cell Signaling Technology, cat.
no. 9106), Bax (N-20; Santa Cruz Biotechnology, Dallas, TX, USA; cat. no. sc-
493), Bcl-2 (C-2; Santa Cruz Biotechnology, cat. no. sc-7382), Noxa (FL-54; Santa
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Cruz Biotechnology, cat. no. sc-30209). DEVDase assay reagents were from
Chemicon. Non-targeting control siRNA (cat. no. D-001810-10-05) was from
Dharmacon (Loughborough, UK) and human Mcl-1-targeted siRNA (cat. no.
SI02781205) was from Qiagen (Valencia, CA, USA). Signalling pathway inhibitors
(Ac.DEVD-CHO, U0126, LY294002, GF109203X, pertussis toxin) were from
Merck Chemicals (Feltham, UK). PI was purchased from Sigma (Gillingham, UK).
Sources of all other materials have been described elsewhere.53–55
Cell culture. CCL39 cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% (v/v) fetal bovine serum,
1 mM L-glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin at 37 1C
in a humidified atmosphere containing 5% (v/v) CO2. Stably transfected clones
were cultured in medium supplemented with 0.6 mg/ml G418 to maintain
selection pressure. HUVECs were propagated in endothelial growth medium-2
(EGM-2) supplemented with 2% (w/v) fetal bovine serum, hydrocortisone,
ascorbate and recombinant growth factors as recommended by the supplier
(Lonza, Verviers, Belgium).
Immunofluorescence and confocal microscopy. S1P1-expressing
CCL39 cells were plated onto glass coverslips in six-well dishes and grown to
confluence. Following serum starvation for 16–24 h and fixed by a 20-min
incubation at room temperature with 4% (w/v) paraformaldehyde in 5% (w/v)
sucrose-phosphate-buffered saline (PBS). Cells were permeabilised in 0.4% (v/v)
Triton X-100 in PBS before sequential incubation with rabbit polyclonal anti-S1P1
antibody and Alexa 488-conjugated goat anti-rabbit IgG. Coverslips were then
mounted onto slides for imaging by confocal microscopy as described
previously.55
FACS analysis of cell cycle progression. Treated control or S1P1-
expressing CCL39 cells were harvested by trypsinisation before re-suspension in
ice-cold 70% (v/v) ethanol in PBS and incubation on ice for 30min and storage at
 20 1C. Following brief centrifugation, cells were washed twice in ice-cold
PBS then resuspended in PBS (0.5 ml) containing 0.1% (v/v) Triton X-100,
RNase A (0.2 mg/ml) and PI (20 mg/ml) for 30min at 37 1C before flow cytometry
on a BD FACSCalibur and analysis using CellQuest Pro (BD Biosciences,
Oxford, UK).
Immunoblotting. Confluent cells in six-well plates were treated as
described in the figures before washing in ice-cold PBS and solubilisation by
scraping into 0.2 ml per well detergent lysis buffer (50 mM sodium HEPES, pH
7.5, 150 mM sodium chloride, 5 mM EDTA, 10 mM sodium fluoride, 10 mM
sodium phosphate, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate,
0.1% (w/v) SDS, 0.1 mM phenylmethylsulphonyl fluoride, 10 mg/ml soybean
trypsin inhibitor, 10 mg/ml benzamidine and EDTA-free complete protease
inhibitor mix). Following brief vortexing and solubilisation by rotation for 30 min,
insoluble material was removed by microcentrifugation and the supernatant
assayed for protein content using a bicinchonic acid assay. Samples equalised
for protein content (typically 10–20 mg/sample) were fractionated by SDS-PAGE
on 10 or 12% (w/v) resolving gels. Following transfer to nitrocellulose,
membranes were blocked for 1 h at room temperature in blocking buffer
(5% (w/v) skimmed milk in PBS containing 0.1% (v/v) Tween-20). Membranes
were then incubated either overnight at 4 1C or for 1 h at room temperature with
primary antibody diluted in fresh blocking buffer. Primary antibodies were each
used at a final concentration of 1 mg/ml. Following three washes in blocking
buffer, membranes were incubated for 1 h at room temperature with appropriate
horseradish peroxidase-conjugated secondary antibody at a 1 in 1000 dilution.
After further washes with blocking buffer and PBS, immunoreactive proteins
were visualised by enhanced chemiluminescence. For phospho-specific
antibodies, primary antibodies were diluted in Tris-buffered saline (TBS), pH
7.5, containing 5% (w/v) IgG-free BSA and 0.1% (v/v) Tween-20, and all
washes were with TBS/0.1% (v/v) Tween-20. Quantification of immunoblots was
by densitometric scanning of non-saturating films using Totallab v2.0 imaging
software (Phoretix, Newcastle upon Tyne, UK).
siRNA-mediated knockdown. HUVECs were plated out at a density of
2 105 cells/ml in six-well plates. The next day, cells were transfected with 15 nM
non-targeting or human Mcl-1-targeted siRNA in a total volume of 0.8 ml EGM-2
per well using 12ml HiPerFect. After 3 h, 1.6 ml/well EGM-2 was added and the
cells left for 48 h before analysis.
Clinicopathological details of ERþ cohort. A total of 195 patients
diagnosed with ERþ ductal breast adenocarcinoma were involved in the study.
All patients were treated solely with tamoxifen (104, 53.3%) or tamoxifen plus
radiotherapy (34, 17.4%) or tamoxifen plus chemotherapy (35, 17.9%) or
tamoxifen plus radiotherapy plus chemotherapy (22, 11.3%) according to protocols
at the time of diagnosis. Median age of the patients was 64 with interquartile range
from 54 to 71. According to pathological grading, 40 (20.5%) cases were first
grade, 98 (50.3%) cases were second grade and 57 (29.2%) cases were third
grade tumours. Median tumour size was determined to be 23mm with interquartile
range from 16 to 33mm. Analysis of lymph nodes indicated that 99 patients
(50.8%) had metastasis in comparison with 81 patients (41.5%) that had no
metastasis in the lymph nodes. According to last patient follow-up dates, 101
(51.8%) patients were alive, 62 (31.8%) patients died of breast cancer and 32
(16.4%) patients died of another cause.
TMA construction. In all, 0.6 mm2 cores of breast cancer tissue were
removed from formalin-fixed paraffin-embedded tissue samples to construct the
TMA blocks. All TMA blocks were constructed in triplicate containing three
individual tumour cores taken from the same embedded tissue sample.
Immunohistochemistry. Immunostaining with specific antibodies and
validation of antibody specificity have been previously reported for this cohort of
patients.44,45
In situ apoptosis detection assay. ApopTag Plus Peroxidase In Situ
Apoptosis Detection Kit (Millipore, Billerica, MA, USA) was used to detect
apoptotic cells. Sections were de-waxed in xylene and rehydrated in ethanol
and water. Antigen retrieval was achieved by incubation for 15min at 25 1C with
20mg/ml proteinase K (Millipore) in PBS, pH 7.4. Endogenous peroxidase activity
was inactivated by incubating sections in 3% (v/v) hydrogen peroxide for 5 min at
room temperature. Positive controls were generated by incubation for 30min at
37 1C with 0.1 U/ml RQ1 RNase-free DNase (Promega, Madison, WI, USA). To
terminate the reaction, sections were incubated for 10min at 65 1C in 1 : 50 stop
solution (Promega) diluted in PBS. Further steps were followed as described by
the supplier. Signals were visualised using 3,3’-diaminobenzidine (Vector
Laboratories, Burlingame, CA, USA). Sections were then counterstained in
Mayer’s haematoxylin and dehydrated in ethanol and xylene before mounting.
Apoptotic indices were calculated by dividing the number of apoptotic cells by the
number of non-apoptotic cells and multiplying by 100.
Scoring and statistical analyses. For the IHC experiments, protein
expression was assessed using the weighted histoscore method described by
Tovey et al.56 Protein expression was evaluated by two independent observers
and the agreement between observers was assessed utilising interclass
correlation analysis. Statistical analyses were performed using SPSS 19.0
(Chicago, IL, USA). Mann–Whitney U-tests were utilised to compare the
expression of markers between different subgroups. Data from CCL39 cells and
HUVECs are presented as means±standard error for the number of experiments
indicated, while representative immunoblotting and FACS experiments are shown
in the figures. Statistical significance was assessed either by one-way ANOVA or
unpaired t-tests with an a probability of 0.05. At least three separate experiments
were used for analysis.
Figure 9 Correlations between elevated S1P1 expression, ERK1,2 pathway activation and enhanced survival in ER
þ breast cancer tumours. (a) High levels of plasma
membrane-localised S1P1 expression correlate significantly with a low apoptosis score (P¼ 0.044). (b) High levels of plasma membrane-localised S1P1 expression are
significantly associated with elevated levels of both cytoplasmic (P¼ 0.038) and nuclear (P¼ 0.0001) active phospho-Ser338 Raf-1. (c) High levels of phosphorylated ERK1,2
are significantly associated with elevated levels of active phospho-Ser338 Raf-1 in both the cytoplasm (P¼ 0.004) and nucleus (P¼ 0.007). (d) High levels of phosphorylated
ERK1,2 in the nucleus are significantly associated with a low apoptosis score (P¼ 0.012)
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